Anti-tumor activity of the TRPM8 inhibitor BCTC in prostate cancer DU145 cells

Oncology Letters

Volumn 11, Issue 1, 2016, Pages 182-188

  Liu, Tao ^a   Fang, Zhihai ^b   Wang, Gang ^b   Shi, Mingjun ^b   Wang, Xiao ^b   Jiang, Kun ^b   Yang, Zhonghua ^b   Cao, Rui ^b   Tao, Huangheng ^b   Wang, Xinghuan ^b   Zhou, Jiajie ^a  

^a JINGZHOU CENTRAL HOSPITAL   (China)

^b WUHAN UNIVERSITY   (China)

Author keywords

BCTC; Inhibitor; Prostate cancer; Targeted therapy; TRPM8

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 6; GLYCOGEN SYNTHASE KINASE 3BETA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; N (4 TERT BUTYLPHENYL) 4 (3 CHLORO 2 PYRIDINYL) 1 PIPERAZINECARBOXAMIDE; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; TRANSIENT RECEPTOR POTENTIAL CHANNEL M8;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL ASSAY; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MTT ASSAY; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCRATCH MOTILITY ASSAY; TRANSWELL INVASION ASSAY; UPREGULATION; WESTERN BLOTTING;

EID: 84948798763     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.3854     Document Type: Article

References (31)

1. Akaza H: Asian trends in primary androgen depletion therapy on prostate cancer. Cancer Biol Med 10: 187-191, 2013.
2. Baade PD, Youlden DR, Cramb SM, Dunn J and Gardiner RA: Epidemiology of prostate cancer in the Asia-Pacific region. Prostate Int 1: 47-58, 2013.
3. Rosenthal SA and Sandler HM: Treatment strategies for high-risk locally advanced prostate cancer. Nat Rev Urol 7: 31-38, 2010.
4. Chen Y, Clegg NJ and Scher HI: Anti-androgens and androgen-depleting therapies in prostate cancer: New agents for an established target. Lancet Oncol 10: 981-991, 2009.
5. Damber JE and Aus G: Prostate cancer. Lancet 371: 1710-1721, 2008.
6. Taplin ME: Drug insight: Role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol 4: 236-244, 2007.
7. Sullivan GF, Amenta PS, Villanueva JD, Alvarez CJ, Yang JM and Hait WN: The expression of drug resistance gene products during the progression of human prostate cancer. Clin Cancer Res 4: 1393-1403, 1998.
8. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG and Sawyers CL: Molecular determinants of resistance to antiandrogen therapy. Nat Med 10: 33-39, 2004.
9. Agus DB, Cordon-Cardo C, Fox W, Drobnjak M, Koff A, Golde DW and Scher HI: Prostate cancer cell cycle regulators: Response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst 91: 1869-1876, 1999.
10. Wissenbach U, Niemeyer BA and Flockerzi V: TRP channels as potential drug targets. Biol Cell 96: 47-54, 2004.
11. Prevarskaya N, Zhang L and Barritt G: TRP channels in cancer. Biochim Biophys Acta 1772: 937-946, 2007.
12. Tsavaler L, Shapero MH, Morkowski S and Laus R: Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins. Cancer Res 61: 3760-3769, 2001.
13. Henshall SM, Afar DE, Hiller J, Horvath LG, Quinn DI, Rasiah KK, Gish K, Willhite D, Kench JG, Gardiner-Garden M, et al: Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res 63: 4196-4203, 2003.
14. Okamoto Y, Ohkubo T, Ikebe T and Yamazaki J: Blockade of TRPM8 activity reduces the invasion potential of oral squamous carcinoma cell lines. Int J Oncol 40: 1431-1440, 2012.
15. Yee NS, Brown RD, Lee MS, Zhou W, Jensen C, Gerke H and Yee RK: TRPM8 ion channel is aberrantly expressed and required for preventing replicative senescence in pancreatic adenocarcinoma: Potential role of TRPM8 as a biomarker and target. Cancer Biol Ther 13: 592-599, 2012.
16. Zhang L and Barritt GJ: Evidence that TRPM8 is an androgen-dependent Ca2+ channel required for the survival of prostate cancer cells. Cancer Res 64: 8365-8373, 2004.
17. Valero ML, Mello de Queiroz F, Stühmer W, Viana F and Pardo LA: TRPM8 ion channels differentially modulate proliferation and cell cycle distribution of normal and cancer prostate cells. PloS One 7: e51825, 2012.
18. Madrid R, Donovan-Rodríguez T, Meseguer V, Acosta MC, Belmonte C and Viana F: Contribution of TRPM8 channels to cold transduction in primary sensory neurons and peripheral nerve terminals. J Neurosci 26: 12512-12525, 2006.
19. Mergler S, Mertens C, Valtink M, Reinach PS, Székely VC, Slavi N, Garreis F, Abdelmessih S, Türker E, Fels G and Pleyer U: Functional significance of thermosensitive transient receptor potential melastatin channel 8 (TRPM8) expression in immortalized human corneal endothelial cells. Exp Eye Res 116: 337-439, 2013.
20. Alao JP: The regulation of cyclin D1 degradation: Roles in cancer development and the potential for therapeutic invention. Mol Cancer 6: 24, 2007.
21. Trudeau ME: Docetaxel: a review of its pharmacology and clinical activity. Can J Oncol 6: 443-457, 1996.
22. Kulkarni P: TRPM8 and prostate cancer: To overexpress or repress, that is the question-comment on “Effects of TRPM8 on proliferation and motility of prostate cancer PC-3 cells” by Yang ZH et al in Asian Journal of Andrology. Asian J Androl 11: 150-151, 2009.
23. Flourakis M and Prevarskaya N: Insights into Ca2+ homeostasis of advanced prostate cancer cells. Biochim Biophys Acta 1793: 1105-1109, 2009.
24. Yang ZH, Wang XH, Wang HP and Hu LQ: Effects of TRPM8 on the proliferation and motility of prostate cancer PC-3 cells. Asian J Androl 11: 157-165, 2009.
25. Wang Y, Wang X, Yang Z, Zhu G, Chen D and Meng Z: Menthol inhibits the proliferation and motility of prostate cancer DU145 cells. Pathol Oncol Res 18: 903-910, 2012.
26. Mälkiä A, Madrid R, Meseguer V, de la Peña E, Valero M, Belmonte C and Viana F: Bidirectional shifts of TRPM8 channel gating by temperature and chemical agents modulate the cold sensitivity of mammalian thermoreceptors. J Physiol 581: 155-174, 2007.
27. Valero M, Morenilla-Palao C, Belmonte C and Viana F: Pharmacological and functional properties of TRPM8 channels in prostate tumor cells. Pflugers Arch 461: 99-114, 2011.
28. Parsons JT, Slack-Davis J, Tilghman R and Roberts WG: Focal adhesion kinase: Targeting adhesion signaling pathways for therapeutic intervention. Clin Cancer Res 14: 627-632, 2008.
29. Slack JK, Adams RB, Rovin JD, Bissonette EA, Stoker CE and Parsons JT: Alterations in the focal adhesion kinase/Src signal transduction pathway corassociate with increased migratory capacity of prostate carcinoma cells. Oncogene 20: 1152-1163, 2001.
30. Page-McCaw A, Ewald AJ and Werb Z: Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 8: 221-233, 2007.
31. MacCorkle RA and Tan TH: Mitogen-activated protein kinases in cell-cycle control. Cell Biochem Biophys 43: 451-461, 2005.